New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
04:55 EDTBLUE, BLUE, BLUE, BLUE, ACE, ACE, ACE, ACE, XLRN, XLRN, XLRN, XLRN, TGTX, TGTX, TGTX, TGTX, NVS, NVS, NVS, NVS, AGIO, AGIO, AGIO, AGIO, AG, AG, AG, AGEuropean Hematology Association to hold a conference
19th Congress of the European Hematology Association will be held in Milan, Italy on June 12-15.
News For BLUE;ACE;XLRN;TGTX;NVS;AGIO;AG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
16:18 EDTNVSNovartis Bioventures reports 21.3% stake in Tokai Pharmaceuticals
Subscribe for More Information
08:07 EDTNVSEnanta regains full rights to EDP-239 for Hep C virus from Novartis
Subscribe for More Information
07:28 EDTXLRNLeerink to hold a roundtable
Subscribe for More Information
September 30, 2014
16:39 EDTNVSCMS discloses drug makers' payments to doctors, WSJ says
Subscribe for More Information
07:30 EDTNVSSachs Associates to hold a conference
14th Annual Biotech in Europe Forum for Global Partnering and Investment to be held in Basel, Switzerland on September 30-October 1.
September 29, 2014
08:07 EDTNVSPhase 2 trial of binimetinib in NRAS melanoma shows promising clinical activity
Subscribe for More Information
September 26, 2014
07:34 EDTAGIOAgios Pharmaceuticals presents AG-120 ongoing Phase 1 study data
Subscribe for More Information
07:30 EDTNVSNovartis drug Signifor LAR recommended by CHMP for EU approval
The Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, adopted a positive opinion for Signifor long acting release, or LAR, formulation to treat adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with a first-generation somatostatin analogue, or SSA. If approved in the EU, this next-generation SSA could fill a current unmet need, providing a new therapeutic option for the approximately 45% of acromegaly patients whose growth hormone, or GH, or insulin-like growth factor-1, or IGF-1, levels remain inadequately controlled despite treatment with currently available SSAs.
September 25, 2014
10:16 EDTAGIOAgios Pharmaceuticals management to meet with Leerink
Subscribe for More Information
05:57 EDTTGTXTG Therapeutics price target raised to $22 from $19 at Brean Capital
Brean Capital raised its price target for TG Therapeutics shares to $22 after the company acquired the rights to TGR-1202 from Rhizen Pharmaceuticals. The firm keeps a Buy rating on the stock.
05:28 EDTNVSNovartis AIN457 meets primary endpoint in two Phase III studies
Subscribe for More Information
September 24, 2014
07:56 EDTAGCFA Society of Philadelphia to host a luncheon meeting
Subscribe for More Information
September 23, 2014
10:02 EDTBLUEOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:16 EDTBLUEbluebird bio initiated with a Buy at Roth Capital
Target $50.
08:33 EDTXLRNAcceleron provides update on clinical trial of dalantercept monotherapy
Subscribe for More Information
07:34 EDTTGTXTG Therapeutics announces exercise of license option for TGR-1202
TG Therapeutics announced that it has exercised its option to license the global rights to TGR-1202, the company's novel, next generation PI3K-delta inhibitor from Rhizen Pharmaceuticals, S A. The company and Rhizen have to date been jointly developing TGR-1202 in a 50:50 joint venture. Given the successful development of TGR-1202, TG Therapeutics elected an early exercise of the company's license option. In exchange for the global license, Rhizen will receive a one-time, upfront cash payment of $4M and approximately 370,000 shares of TG Therapeutics' common stock. TG Therapeutics will receive exclusive worldwide rights, excluding India, for the development and commercialization of TGR-1202 for all indications. Rhizen will be eligible to receive regulatory filing, approval and sales based milestones in the aggregate of approximately $240M, and tiered royalties based on net sales.
September 22, 2014
16:07 EDTNVSAnacor announces commercial launch of KERYDIN topical solution in U.S.
Subscribe for More Information
05:57 EDTXLRNAcceleron to host webinar
Subscribe for More Information
September 18, 2014
09:31 EDTXLRNAcceleron management to meet with JMP Securities
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use